



175 Portland St, 4th Floor
Boston, MA 02114
+1 (617) 622-4003
zafgen.com

Dear PWS Community,

As you may have seen in a press release on July 19, 2016, Zafgen announced that the company has made the difficult decision to cease development of beloranib in Prader-Willi syndrome (PWS).

In December 2015, the FDA placed beloranib on full clinical hold suspending all development work following two deaths in the bestPWS trial that resulted from pulmonary emboli in two patients receiving beloranib.

For the past seven months, we have been conducting an in-depth analysis of the data from our clinical trials in an effort to uncover the direct cause of the thrombotic events seen in the bestPWS clinical trial and to pinpoint a marker that would help identify patients who might be at a higher risk for thrombotic events if taking the drug. We also met with thrombosis experts, PWS experts and the FDA to discuss a potential path forward for beloranib.

Following these exhaustive efforts, we concluded that there is not a viable pathway forward for beloranib that can assure patient safety. The benefit/risk ratio is unbalanced toward increased risk and uncertainty and the path for drug approval is unclear, even in combination with anticoagulant drugs, and we cannot move forward under these circumstances. While this is not the outcome that we have collectively worked so hard for, we felt that terminating the beloranib program was the most responsible decision at this time.

Throughout our journey with beloranib in PWS, we have been overwhelmed by the commitment from the entire PWS community. We are deeply grateful to all of those that participated in our clinical trials and supported us over the years. The PWS community has been amazing to work with, and we have made many friends along the way. We also appreciate the efforts of other companies working to advance potential new treatments for PWS, and we will do what we can to share the knowledge we have gained about PWS and drug development as they seek successful outcomes for new therapies that we know are so desperately needed.

On behalf of the entire Zafgen team, I wish you all the best.

Sincerely,

A handwritten signature in blue ink, appearing to read "T. Hughes", with a long horizontal flourish extending to the right.

Thomas Hughes, Ph.D.

President & Chief Executive Officer of Zafgen